Topical and Systemic Retinoids in the Management of Hidradenitis Suppurativa: A Comprehensive Literature Review.
Elisa MolinelliHelena GioacchiniAndrea MaraniGiulio RizzettoDaisy GambiniEdoardo De SimoniAnnamaria OffidaniOriana SimonettiPublished in: Dermatology and therapy (2024)
Hidradenitis suppurativa (HS) is a debilitating chronic skin disorder characterized by painful inflammatory nodules, abscesses and sinus tracts involving intertriginous areas and has an adverse impact on patient quality of life. Over the past decade, the therapeutic options of HS have increased significantly to comprise multiple modalities, including topical medication, systemic therapies (mainly antibiotics, retinoids, and biologics), surgical approaches, and lifestyle modifications. Biologics alone or in combination with surgery remain the treatment of choice for moderate to severe disease. However, non-biologic therapies (including retinoids) may be used as monotherapy for mild disease and in combination with biologics and surgical treatment in moderate to severe disease. Retinoids, specifically isotretinoin, acitretin, and alitretinoin, are historically used in the management of HS, supported by anecdotal evidence and with variable treatment response. Although the current American and European guidelines offer different recommendations on the use of retinoids in HS, retinoids remain a valuable ally in HS management. This review provides a comprehensive analysis of the current scientific literature on retinoid therapy (topical and systemic) in HS, highlighting disparities in mechanisms of action, efficacy, and safety to clarify their role in HS treatment.
Keyphrases
- hidradenitis suppurativa
- case report
- wound healing
- systematic review
- healthcare
- rheumatoid arthritis
- cardiovascular disease
- high intensity
- metabolic syndrome
- clinical practice
- minimally invasive
- drug induced
- early onset
- combination therapy
- emergency department
- oxidative stress
- soft tissue
- randomized controlled trial
- clinical trial
- open label
- health insurance
- study protocol
- replacement therapy
- percutaneous coronary intervention
- affordable care act